Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Middle East Conflict Impacts Australia and New Zealand Businesses 
ALAMEDA, Calif, May 08, 2018 -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the first quarter of 2018, ended March 31, 2018, on Tuesday, May 15, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, May 15, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
The dial-in number in the U.S./Canada is 800-263-0877; for international participants, the number is +1-323-794-2094. For all callers, please refer to Conference ID 6365614. To access the live webcast, go to the investor relations section on the Company’s website, http://investors.oncocyte.com/events-and-presentations.
A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling 888-203-1112 toll-free (from U.S./Canada); international callers dial 719-457-0820. Use the Conference ID 6365614. Additionally, the archived webcast will be available at http://investors.oncocyte.com/events-and-presentations.
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy and cystoscopic procedures. OncoCyte’s development pipeline is focused on non-invasive confirmatory diagnostic tests for lung, breast, and bladder cancer. OncoCyte’s tests are being developed using proprietary sets of genetic and protein molecular markers that differentially express in specific types of cancer. OncoCyte conducts ongoing research to identify additional molecular markers, acquire or license markers and related technology, and develop tests based on those markers.
Contact
EVC Group LLC
Matt Haines / Michael Polyviou
917-733-9297 / 732-933-2754
[email protected] / [email protected]
